Towards treatment personalisation in triple negative breast cancer: role of platinum-based neoadjuvant chemotherapy

Breast Cancer Res Treat. 2018 Nov;172(1):239-240. doi: 10.1007/s10549-018-4885-9. Epub 2018 Jul 12.

Authors

Mattia Rediti¹, Carlo Messina²

Affiliations

¹ Medical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
² Academic Unit of Medical Oncology, Department of Internal Medicine, School of Medicine, Policlinico Hospital San Martino-IST, University of Genoa, Largo R. Benzi 10, 16132, Genoa, Italy. carlo.messi@hotmail.it.

PMID: 30003394
DOI: 10.1007/s10549-018-4885-9

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Meta-Analysis as Topic
Neoadjuvant Therapy
Platinum / administration & dosage
Precision Medicine / methods
Treatment Outcome
Triple Negative Breast Neoplasms / diagnosis
Triple Negative Breast Neoplasms / drug therapy*
Triple Negative Breast Neoplasms / etiology

Substances

Platinum